company background image
NUVL

Nuvalent NasdaqGS:NUVL Stock Report

Last Price

US$17.44

Market Cap

US$844.3m

7D

-2.2%

1Y

-21.2%

Updated

27 Sep, 2022

Data

Company Financials +
NUVL fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

NUVL Stock Overview

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer.

Nuvalent, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Nuvalent
Historical stock prices
Current Share PriceUS$17.44
52 Week HighUS$31.43
52 Week LowUS$7.09
Beta0
1 Month Change10.80%
3 Month Change25.02%
1 Year Change-21.23%
3 Year Changen/a
5 Year Changen/a
Change since IPO-6.99%

Recent News & Updates

Sep 13
Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Aug 10

Nuvalent GAAP EPS of -$0.38 beats by $0.03

Nuvalent press release (NASDAQ:NUVL): Q2 GAAP EPS of -$0.38 beats by $0.03. Cash, cash equivalents and marketable securities were $257.0 million

Shareholder Returns

NUVLUS BiotechsUS Market
7D-2.2%-3.3%-5.8%
1Y-21.2%-27.4%-22.1%

Return vs Industry: NUVL exceeded the US Biotechs industry which returned -30.6% over the past year.

Return vs Market: NUVL exceeded the US Market which returned -23.7% over the past year.

Price Volatility

Is NUVL's price volatile compared to industry and market?
NUVL volatility
NUVL Average Weekly Movement12.8%
Biotechs Industry Average Movement11.0%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: NUVL is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: NUVL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201752Jim Porterhttps://www.nuvalent.com

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Nuvalent, Inc. Fundamentals Summary

How do Nuvalent's earnings and revenue compare to its market cap?
NUVL fundamental statistics
Market CapUS$844.32m
Earnings (TTM)-US$65.73m
Revenue (TTM)n/a

0.0x

P/S Ratio

-12.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NUVL income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$65.73m
Earnings-US$65.73m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.36
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did NUVL perform over the long term?

See historical performance and comparison